title: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
abstract: OBJECTIVE
  To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  
  
  METHODS
  p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries. Nuclear p53 and membranous HER2/neu immunostaining were evaluated.
  
  
  RESULTS
  Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors. HER2/neu immunostaining was observed in one normal ovary. P53 overexpression was found in 25% EOC and was related with advanced stage, endometrioid, clear cell and undifferentiated types, grade G3, and sub-optimal surgery. HER2/neu immunostaining was observed in 24.2% and it was associated with advanced stage, clear cell and undifferentiated types, and suboptimal surgery. Both, p53 and HER2/neu overexpression decreased overall and progression-free survival, but in the multivariant analysis, only HER2/neu overexpression was an independent prognostic factor of overall survival (RR = 2.8; 95% confidence interval [CI], 1.2-5.6) and recurrence (RR = 2.8; 95% CI, 1.1-7.1). Simultaneous p53 and HER2/neu overexpression made the prognosis worse (p < 0.01).
  
  
  CONCLUSIONS
  HER2/neu overexpression (but not p53 overexpression) is a major prognostic factor in EOC.
authors.affiliation: Departamento de Obstetricia y Ginecología, Hospital Clínico San Carlos, Martín Lagos s/n, 28040 Madrid, Spain. pcoronadom@sego.es
authors.forename: Pluvio J
authors.initials: PJ
authors.lastname: Coronado Martín
authors.forename: María
authors.initials: M
authors.lastname: Fasero Laiz
authors.forename: Javier
authors.initials: J
authors.lastname: García Santos
authors.forename: Mar
authors.initials: M
authors.lastname: Ramírez Mena
authors.forename: José A
authors.initials: JA
authors.lastname: Vidart Aragón
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor; D016001:Confidence Intervals; D018291:Cystadenoma, Mucinous / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D018293:Cystadenoma, Serous / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D004715:Endometriosis / Q000235:genetics / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010049:Ovarian Diseases / Q000235:genetics / Q000473:pathology / Q000601:surgery; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D012306:Risk; D016019:Survival Analysis; D013724:Teratoma / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000601:surgery; D013997:Time Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53